Tirzepatide vs Semaglutide for Weight Loss

If you've been reading about GLP-1 medications, two names come up again and again: semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Both are FDA-approved injectable medications, both produce meaningful weight loss in clinical trials, and both work by acting on gut hormone pathways. But they are not identical. This guide breaks down the differences in plain language so you can have a better-informed conversation with a licensed clinician. This is educational content only — it is not medical advice, and nothing here should be treated as a personal prescription.

How each one works

The core difference is the number of receptors each drug targets.

• Semaglutide is a single-agonist: it mimics GLP-1 (glucagon-like peptide-1), a hormone that slows stomach emptying, curbs appetite, and improves insulin response.
• Tirzepatide is a dual-agonist: it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The addition of GIP activity is thought to contribute to its stronger effect on appetite and metabolism, though researchers are still studying exactly why.

In practical terms, both reduce hunger and help you feel full sooner. Tirzepatide's dual mechanism is one reason head-to-head data tends to favor it for total weight reduction.

What the trials suggest

Clinical trials aren't a promise of individual results, but they give a useful benchmark. In the STEP program, semaglutide 2.4 mg weekly produced average weight loss in the mid-teens as a percentage of body weight over roughly 68 weeks. In the SURMOUNT program, tirzepatide at its higher maintenance doses produced average reductions in the low-to-mid twenties percent over a comparable period.

A direct head-to-head study (SURMOUNT-5) compared the two and reported greater average weight loss with tirzepatide. That said, "greater on average" does not mean "better for everyone." Response varies widely from person to person, and the medication you tolerate best is often the one that works best for you in real life.

Dosing basics and titration

Both medications are once-weekly subcutaneous injections, and both use a gradual dose-escalation schedule. Starting low and increasing slowly is what helps the body adjust and keeps nausea manageable. Rushing the titration is one of the most common mistakes people make.

• Semaglutide for weight management typically climbs in steps toward a 2.4 mg weekly target.
• Tirzepatide climbs in steps toward maintenance doses that can reach 15 mg weekly.

Because the two drugs use completely different milligram scales, you can't compare "5 mg of one" to "5 mg of the other." If you're mapping out reconstitution and draw volumes, our tirzepatide dosage calculator and semaglutide dosage calculator can help you visualize the math — always under the guidance of the clinician who prescribed your medication. For unit conversions specifically, the semaglutide unit conversion guide is a handy reference.

Side effects: mostly the same family

The side-effect profiles overlap heavily because both act on GLP-1. The most common complaints are gastrointestinal:

• Nausea, especially early in titration
• Constipation or diarrhea
• Reduced appetite and occasional reflux
• Fatigue during the adjustment period

More serious but less common concerns — pancreatitis, gallbladder issues, and boxed warnings related to thyroid C-cell tumors in animal studies — apply to both drug classes and are reasons to work closely with a clinician. Because tirzepatide is often used at higher potency, some people find they need to titrate even more patiently. Eating smaller meals, staying hydrated, and slowing dose increases are common ways people manage the transition.

Cost, access, and choosing between them

Both are brand-name medications and can be expensive without insurance coverage, and availability has fluctuated with demand. Rather than assume one is "the winner," most clinicians weigh several factors: your health history, tolerance, other medications, insurance, and goals. If cost is part of your decision, our tirzepatide cost overview lays out the factors involved without promising any specific price.

A few honest takeaways:

• Tirzepatide tends to produce more weight loss on average in trials.
• Semaglutide has a longer real-world track record and more cardiovascular outcome data behind it.
• The right choice is individual, and it may change over time.

What about newer compounds?

You'll also see discussion of retatrutide (a triple-agonist targeting GLP-1, GIP, and glucagon) and cagrilintide (an amylin analog often paired with semaglutide). These are investigational and not FDA-approved as finished drugs. Early data looks promising, but they remain in clinical development, and any use would require a licensed clinician's oversight. You can read our educational overview on the retatrutide side effects page if you're curious about where the research stands.

Bottom line

Tirzepatide and semaglutide are both effective, FDA-approved options, and the head-to-head evidence gives tirzepatide an edge in average weight loss. But "average" isn't "you." The best medication is the one that fits your body, your health picture, and a plan you can actually stick with — decided together with a qualified prescriber. If you want to keep your injections organized once you and your clinician settle on a plan, a simple dose tracker can help you stay consistent and spot patterns over time.